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to protein aggregation in ALS. The precise pathological 
effects of protein aggregation remain largely unknown, but 
experimental evidence hints at both gain- and loss-of-func-
tion mechanisms. Here, we discuss recent advances in our 
understanding of the molecular make-up, formation, and 
mechanism-of-action of protein aggregates in ALS. Further 
insight into protein aggregation will not only deepen our 
understanding of ALS pathogenesis but also may provide 
novel avenues for therapeutic intervention.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease caused by the loss of both upper and 
lower motor neurons. Affected patients develop progressive 
muscle weakness eventually leading to death due to res-
piratory failure, typically 3–5 years after symptom onset. 
ALS affects ~2 out of 100,000 individuals per year [76]. In 
the majority of patients the disease occurs sporadic and is 
referred to as sporadic ALS (SALS). In 5 % of cases there 
is a family history of ALS (FALS) [29]. The presence of 
protein aggregates in affected motor neurons is a charac-
teristic, but still poorly understood hallmark of SALS 
and FALS patients. Recently, many new ALS causing 
gene defects have been identified including mutations in 
HNRNPA1, PFN1, C9ORF72, UBQLN2, OPTN, VCP, FUS 
and TARDBP [1, 105]. Most of these mutations are rare and 
cause ALS in a small subgroup of patients. Remarkably, 
however, the proteins encoded by these genes are present 
in protein aggregates of a large proportion of non-mutation 
Abstract Amyotrophic lateral sclerosis (ALS) is a neu-
rodegenerative disease characterized by the aggregation of 
ubiquitinated proteins in affected motor neurons. Recent 
studies have identified several new molecular constitu-
ents of ALS-linked cellular aggregates, including FUS, 
TDP-43, OPTN, UBQLN2 and the translational product 
of intronic repeats in the gene C9ORF72. Mutations in the 
genes encoding these proteins are found in a subgroup of 
ALS patients and segregate with disease in familial cases, 
indicating a causal relationship with disease pathogenesis. 
Furthermore, these proteins are often detected in aggre-
gates of non-mutation carriers and those observed in other 
neurodegenerative disorders, supporting a widespread role 
in neuronal degeneration. The molecular characteristics 
and distribution of different types of protein aggregates in 
ALS can be linked to specific genetic alterations and shows 
a remarkable overlap hinting at a convergence of underly-
ing cellular processes and pathological effects. Thus far, 
self-aggregating properties of prion-like domains, altered 
RNA granule formation and dysfunction of the protein 
quality control system have been suggested to contribute 
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carriers indicating a more widespread role for their abnor-
mal localization in ALS pathogenesis (Table 1). Moreover, 
some of these proteins are present in pathological aggre-
gates of other neurodegenerative disorders such as fron-
totemporal lobar degeneration (FTLD), spinocerebellar 
ataxia (SCA), Huntington’s disease, Alzheimer’s disease 
and inclusion body myositis (IBM), indicating a more gen-
eral involvement in neurodegeneration.
Despite clear evidence that protein aggregation is central 
to the pathology of ALS many questions remain about the 
role, formation and mechanism-of-action of protein aggre-
gates in ALS. What drives deposition of proteins in ALS? 
Which cellular mechanisms contribute to protein aggrega-
tion or are affected by it? Furthermore, what is the role of 
proteins carrying ALS-associated mutations in aggregate 
formation? Pathological, cell culture and animal studies 
are now beginning to provide insights into these important 
questions. We will give an overview of the characteristics 
of aggregates observed in motor neurons of ALS patients 
and the relationship between protein aggregation, neuro-
toxicity and disease severity in cellular and animal model 
systems. We will then discuss possible underlying molecu-
lar mechanisms in protein aggregation and neuronal degen-
eration and provide directions for future research. Although 
an ever-increasing number of proteins is being implicated 
in ALS pathogenesis, the emphasis here is on the most 
recently discovered proteins and those present in spinal 
cord aggregates.
Novel insights into the molecular makeup and 
formation of cellular aggregates in ALS
The central pathological hallmark of ALS is the presence of 
cytoplasmic inclusions or aggregates in degenerating motor 
neurons and surrounding oligodendrocytes. Inclusions are 
not restricted to the spinal cord but also present in other 
brain regions such as the frontal and temporal cortices, 
hippocampus and cerebellum [1]. The predominant aggre-
gates found in ALS patients are ubiquitinated aggregates 
that are classified as either Lewy body-like hyaline inclu-
sions or skein-like inclusions. At the ultrastructural level, 
Lewy body-like or skein-like inclusions appear as ran-
domly oriented filaments covered by fine granules [78, 129, 
166]. Additional subclasses of aggregates found in ALS 
are Bunina bodies, which are small eosinophilic ubiqui-
tin-negative inclusions [158] and round hyaline inclusions 
without a halo. Bunina bodies consist of amorphous elec-
tron-dense material surrounded by tubular and vesicular 
structures [158]. Furthermore, neurofilamentous inclusions 
are found in the axon hillock in close proximity to ubiqui-
tinated inclusions. Other cellular abnormalities include the 
presence of mitochondrial vacuolization, fragmentation of 
the Golgi apparatus and abnormalities at the neuromuscular 
junction. In 1993, SOD1 was the first protein to be iden-
tified to aggregate in FALS cases carrying a mutation in 
the SOD1 gene [167]. Later, mutations in VAPB were also 
shown to cause ALS in a group of FALS patients [154]. 
Due to exponential development of genetic techniques, 
several new proteins have been identified to be involved in 
ALS pathophysiology during the past few years, including 
TDP-43, FUS, OPTN, UBQLN2 and C9ORF72. In the fol-
lowing sections, we will discuss for each of these proteins 
the characteristics of the aggregated protein, their physi-
ological functions and effects in ALS disease models.
TAR DNA-binding protein 43 (TDP43)
Following the identification of SOD1 aggregates in a small 
subset of ALS patients, a breakthrough was achieved in 
2006 with the identification of TDP-43 as a major compo-
nent of ubiquitinated inclusions in FTLD and ALS cases 
[6, 150]. Non-mutated TDP-43 is found in aggregates in 
spinal cord motor neurons, hippocampal and frontal cor-
tex neurons and glial cells in all SALS patients and the 
vast majority of SOD-1-negative FALS patients, but not in 
SOD1 related ALS [133, 181] (Table 1). In frontotempo-
ral dementia (FTD), TDP-43 aggregates are present in the 
most common subtype of the disease, FTLD with ubiqui-
tinated inclusions, now referred to as FTLD-TDP [150]. 
ALS and FTD show a remarkable overlap at the genetic, 
symptomatic and pathological level and they may actually 
reflect two ends of a disease spectrum [33, 66]. TDP-43 
is also found to accumulate in Alzheimer’s disease, Lewy 
body disease and SCA2, secondary to other molecules [3, 
7, 60, 82] and even in normal control subjects over the age 
of 65 [67].
Normally TDP-43 predominantly localizes to the 
nucleus. In ALS patients, cytoplasmic aggregation is often 
accompanied by nuclear clearing of the protein [133, 150]. 
Furthermore, the protein is cleaved in C-terminal fragments 
of 18–26 and 35 kDa and the full-length protein and 18–
26 kDa fragments are hyperphosphorylated [78, 91, 150]. 
Genetic studies have identified mutations in the gene encod-
ing TDP-43, TARDBP, in 1–2 % of FALS and SALS cases 
[100, 192]. In non-ALS inclusions TDP-43 is also cleaved 
and hyperphosphorylated. However, banding patterns of 
TDP-43 cleavage products are distinct between ALS and 
FTLD-B and other FTLD subtypes [78, 91, 189]. Further-
more, the distribution of the TDP-43-positive aggregates is 
disease-specific with, for example, involvement of spinal 
cord motor neurons in ALS and a more widespread distribu-
tion in the brain in FTLD [12]. Mutations in TARDBP are 
unique to ALS and are not found in other neurodegenerative 
disorders [28, 168, 192] with the exception of a small num-
ber of FTD cases [18, 23, 24, 34, 35, 38, 111, 145].
780 Acta Neuropathol (2013) 125:777–794
1 3
TDP-43 is a DNA and RNA binding protein that binds 
around 30 % of the mouse transcriptome with a prefer-
ence for long UG-rich sequences [163, 185] (Fig. 1). Target 
sequences are mainly intronic, but also include non-coding 
RNAs and 3′ UTRs. In line with this, TDP-43 plays a role 
in nuclear RNA metabolism including splicing, transcrip-
tional repression, miRNA synthesis, mRNA nucleo-cyto-
plasmic shuttling and RNA transport [117]. The majority 
of TDP-43 mutations identified to date are localized in the 
C-terminal glycine-rich domain of the protein (Fig. 1). This 
domain binds other hnRNPs and is important for the splic-
ing activity of TDP-43 [41].
Purified TDP-43 is prone to aggregation and this aggre-
gation tendency depends on its C-terminal domain and is 
enhanced by ALS-linked TDP-43 mutations [94, 95]. In 
line with endogenous staining patterns, overexpression of 
TDP-43 causes a predominant nuclear localization [99, 
130, 176, 199]. In addition, a small proportion of primary 
neuronal cells shows cytoplasmic localization, which is 
enhanced when TDP-43 mutants are overexpressed [13, 
54, 73, 99]. Recently, the first induced pluripotent stem cell 
(iPSC)-derived motor neurons were generated from fibro-
blasts of patients carrying a M337V TARDBP mutation 
[22]. Similar to control, the M337V TARDBP line showed 
predominant nuclear localization of TDP-43 but with addi-
tional granular staining in soma and neurites [22].
Overexpression of WT TDP-43 has a toxic effect in 
yeast and cultured primary neurons derived from rat or 
mouse embryo’s. This effect is even more prominent when 
mutant TDP-43 is overexpressed [13, 54, 73, 95, 99]. In 
most animal studies, overexpression of WT or mutant 
TDP-43 induces a motor phenotype and reduces life span, 
but results so far are limited to the toxic effects of TDP-
43 overexpression [12] (Supplementary Table). Although 
some studies report on increased toxicity in mutant as 
compared to WT transgenic lines [9, 180, 222], other stud-
ies do not report such differences [177, 212, 213]. As the 
toxic effects of TDP-43 are clearly dose-dependent [177, 
208, 213], some of these results may be dependent on the 
level of expression rather than on TDP-43 mutation-spe-
cific toxic effects. Furthermore, while it has been reported 
that TDP-43 WT overexpression has motor neuron-specific 
toxic effects coinciding with the presence of nuclear and 
cytoplasmic inclusions and pathological phosphorylation 
and cleavage of TDP-43 [89, 208, 213], overexpression of 
TDP-43 can be toxic without aggregate formation [9, 205].
Several factors modulate TDP-43 toxicity. First, the 
TDP-43 C-terminal fragments that are found in ALS spinal 
Fig. 1  Schematic representation of the domain organization of TDP-
43, FUS, ATXN2, OPTN and UBQLN2. Different protein domains 
are indicated in different colors (see legend). The location of ALS-
associated genetic alterations is depicted by sticks (mutations) or 
arrowheads (repeats). For C9ORF72 intronic and exonic regions are 
depicted; an intronic hexanucleotide repeat is causative of ALS/FTD 
(arrowhead). Boxes show a selection of relevant interactors for each 
of the depicted proteins
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cord aggregates are particularly aggregation-prone and 
toxic when overexpressed [13, 54, 88, 156, 221]. Second, 
the cytoplasmic distribution of TDP-43 has been reported 
to be related to cell death whereas inclusion body forma-
tion or nuclear TDP-43 levels were not [13]. In line with 
this, mutations of the nuclear localization signal (NLS) of 
TDP-43 confer toxicity while NES mutations abrogate tox-
icity [13]. Third, phosphorylation of TDP-43 may modu-
late aggregation and toxicity of the protein [26, 126]. In 
C. elegans blockage of TDP-43 phosphorylation ameliorates 
the neurodegenerative effect of ALS-associated TDP-43 
mutants [126, 127]. In contrast, another study reported 
that mutation of phosphorylation sites increased aggregate 
formation in cells and in Drosophila, whereas hyperphos-
phorylation reduced aggregation and toxicity [123]. In 
addition, mutation of TDP-43 phosphorylation sites does 
not affect C-terminal fragment formation, the formation of 
cytoplasmic inclusions or survival in cells [51, 153, 221]. 
Thus, although it is clear that TDP-43 plays a crucial and 
central role in ALS pathology many questions remain about 
its pathological mechanisms in ALS.
Fused in sarcoma/translocated in liposarcoma (FUS/TLS)
The discovery of ALS-linked mutations in TDP-43 fueled 
the identification of mutations in another RNA binding pro-
tein, FUS, in FALS patients [116, 196]. A series of genetic 
studies of large ALS cohorts showed that FUS mutations 
account for 4 % of FALS and 1 % of SALS cases and that 
these are in part associated with young-onset disease [117]. 
Pathological examination of post-mortem tissue of FUS 
mutation carriers shows predominant degeneration of lower 
motor neurons with FUS-positive cytoplasmic inclusions 
and a normal distribution of TDP-43, thereby distinguish-
ing them from other ALS cases [72, 80, 116, 196]. The pre-
cise pattern of FUS-immunoreactivity in ALS cases with-
out FUS mutations is still unclear (Table 1). Some studies 
report that FUS is not present in SALS patients and SOD1 
FALS [87, 149, 196], while others show FUS-positive 
inclusions with signals for TDP-43, p62 and ubiquitin in 
all SALS and FALS cases, except for SOD1 mutation carri-
ers [48, 103]. In contrast to TDP-43, biochemical analyses 
show that mutant FUS protein itself is not ubiquitinated, 
hyperphosphorylated or cleaved. However, the protein is 
enriched in the insoluble fraction of FTLD-FUS brains 
[149]. Furthermore, nuclear clearing of FUS is not as evi-
dent as observed for TDP-43.
FUS has also been detected in aggregates found in other 
neurodegenerative disorders including FTLD, Hunting-
ton’s disease and SCA indicating that disruption of WT 
FUS function is associated with neurodegenerative disease 
in general [50, 149]. However, in contrast to ALS, FTLD 
patients with FUS inclusions only rarely harbor genetic 
alterations in FUS [195]. Interestingly, FUS-positive inclu-
sions in FTLD cases are immunoreactive for TAF15 and 
EWS, other members of the FET family of RNA binding 
proteins, and for transportin-1 [147, 151]. Protein aggre-
gates in ALS cases with FUS mutations do not stain for 
these proteins.
FUS is a nuclear RNA binding protein and preferentially 
binds pre-mRNA at intronic sites, but also long non-coding 
RNAs, exons and 3′UTRs [84] (Fig. 1). Most of the ALS-
linked FUS mutations reported to date are localized in the 
NLS of the protein resulting in impaired nuclear transport 
of FUS [52]. FUS mediates a wide range of cellular pro-
cesses including DNA repair, transcription, splicing and 
miRNA processing [117]. The protein shuttles between the 
nucleus and the cytoplasm to function in the transport of 
mRNA [224].
Purified FUS is aggregation prone, but in contrast to 
TDP-43 this property may not be influenced by ALS-linked 
mutations [179]. In yeast, cytosolic aggregation of FUS 
depends on its N-terminal, RRM and first RGG domains 
(Fig. 1). Toxicity is dependent on the N-terminal and first 
RGG domains [97, 179]. It should be noted, however, that 
the NLS of FUS is not fully recognized in yeast suggest-
ing that this domain may still be involved in protein aggre-
gation. Following overexpression in eukaryotic cells, WT 
FUS localizes to the nucleus, whereas FUS proteins car-
rying ALS mutations in the NLS form cytoplasmic aggre-
gates, thereby mimicking human disease [116, 196]. This 
cytoplasmic relocalization is observed in some but not all 
FUS animal models reported to date [25, 32, 42, 86, 119, 
142, 198, 203, 211] (Supplementary Table).
Deletion of the NES in FUS strongly reduces toxicity 
of mutant FUS in Drosophila [119], suggesting that the 
cytoplasmic localization of mutant FUS confers toxicity. 
However, another study reported that deletion of the NLS 
completely blocks FUS toxicity, as did the addition of a 
NES [211]. Blocking the RNA binding capacity of FUS 
also abolishes FUS toxicity in yeast [178] and ameliorates 
mutant FUS toxicity in Drosophila [42] (Supplementary 
Table). Although further work is needed to reveal to which 
extent mislocalization of mutant FUS contributes to dis-
ease, recent studies show that mutant FUS triggers stress 
granule formation and loss of nuclear GEMs, as will be dis-
cussed in more detail in the next section.
Optineurin (OPTN)
A study on Japanese ALS patients from consanguineous 
marriages reported mutations in OPTN to be associated 
with disease [135]. Although genetic variation in OPTN 
is rare in ALS patients in other populations, pathologic 
studies confirm a role for OPTN in ALS. In SALS cases, 
OPTN is present in cytoplasmic skein-like inclusions and 
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colocalizes with ubiquitin, TDP-43, and possibly FUS 
[46, 85, 103, 135, 159] (Table 1). Conflicting results are 
obtained with respect to OPTN immunoreactivity in SOD1 
and FUS mutation carriers. Two studies detected colocali-
zation of OPTN with SOD1-positive inclusions in SOD1 
mutation carriers [103, 135], while two other studies did 
not [46, 85]. Similarly, two studies reported OPTN immu-
noreactivity in FUS mutation carriers [92, 103], while a 
second group could not detect OPTN-positive inclusions 
[85].
OPTN is present in inclusions in several other neurode-
generative diseases such as ALS with dementia, Hunting-
ton’s disease, Alzheimer’s disease, Parkinson’s disease, 
Creutzfeldt-Jakob disease, multiple system atrophy and 
Pick disease [159].
OPTN functions as an inhibitor of NFκB-signaling 
[223], acts as an autophagy receptor [206] and participates 
in the regulation of vesicular trafficking and maintenance 
of the Golgi apparatus [169] (Fig. 1). Purified OPTN is not 
aggregation prone although strong overexpression in yeast 
results in aggregation of the protein and in toxicity [113]. 
This toxicity requires the Rab8 binding region but not the 
ubiquitin-binding domain of OPTN. Mutations identified 
in ALS patients so far include truncation mutations thought 
to act through loss-of-function mechanisms and missense 
mutations [17, 45, 90, 135, 141, 191]. OPTN E478G, car-
rying a mutation in the UBAN domain, looses its ability 
to bind K63-polyubiquitin or linear-polyubiquitin chains 
[206] and fails to inhibit NFκB [135]. Whereas exog-
enous WT OPTN localizes to LC3-positive vesicles upon 
autophagy induction [174, 206], OPTN E478G does not 
[206]. As the ubiquitin binding capacity of OPTN is neces-
sary to serve as an LC3 adaptor, this likely reflects a loss 
of binding to autophagosomes [206]. However, whether 
the inability of OPTN E478G to bind ubiquitin is related 
to ALS pathophysiology is unknown. It is interesting to 
note that homozygous knock-in mice expressing a OPTN 
D477N mutant, which also lacks ubiquitin binding capac-
ity, do not display an ALS-like phenotype [70]. The OPTN 
truncation mutants reported in ALS patients have been pro-
posed to cause decreased OPTN protein levels. In this light 
it is interesting that knockdown of OPTN results in motor 
neuron phenotypes in zebrafish [110]. Whether incorpora-
tion of OPTN in ALS aggregates in non-mutation carri-
ers also results in loss of function of the protein or merely 
reflects its role as an autophagic receptor warrants further 
investigation.
Ubiquilin-2 (UBQLN2)
Dysfunction of the ubiquitin–proteasome system (UPS) 
has been linked to ALS based on a variety of functional 
studies. The contribution of this process to motor neuron 
degeneration is further underlined by the recent identifi-
cation of mutations in UBQLN2 in X-linked ALS/FTD 
[47]. In human spinal cord autopsy material of UBQLN2 
mutation carriers, skein-like inclusions are positive for 
UBQLN2, ubiquitin, p62, TDP-43, FUS and OPTN but 
not SOD1 [47, 207] (Table 1). In cases with ALS-dementia 
with or without UBQLN2 mutations, UBQLN2-positive 
inclusions are found in the hippocampus which are absent 
in ALS cases without dementia indicating that UBQLN2 
aggregation and neurodegeneration are linked [47]. Skein-
like inclusions in spinal cord tissue from SALS and FALS 
patients with unknown mutations or mutations in SOD1, 
TDP-43 or FUS also stain positive for UBQLN2 [47, 
207]. It is currently unknown whether UBQLN2 is pre-
sent in aggregates in other neurodegenerative diseases and 
a first study did not detect mutations in UBQLN2 in FTD 
[79]. Whether the presence of UBQLN2 in ALS aggre-
gates reflects a cellular attempt for protein degradation or 
is related to dysfunction of protein degradation pathways 
needs to be further investigated.
The exact function of UBQLN2 is unknown, but it has 
been implicated in protein degradation via both UPS and 
autophagy and in G-protein coupled receptor endocyto-
sis [121] (Fig. 1). Overexpression of mutant UBQLN2 
has been shown to result in impaired UPS function [47]. 
Most, but not all ALS-associated mutations identified 
in UBQLN2 to date involve proline residues in its PXX 
region, which is thought to be important for protein–pro-
tein-interactions. Further research is needed to determine 
how mutant UBQLN2 impairs protein degradation systems 
and which proteins are affected.
Ataxin-2 (ATXN2)
A yeast screen for modifiers of TDP-43 toxicity recently 
led to the discovery that extended polyQ repeats in ATXN2 
are associated with ALS [53]. While ATXN2 normally 
harbors 21 or 22 polyQ repeats, and a polyQ length of 34 
and higher is known to cause SCA2 [120], polyQ lengths 
between 27 and 33 are associated with ALS [53]. Spinal 
cord tissue of SALS patients shows an increased cytoplas-
mic accumulation of ATXN2, as compared to controls, 
but there is no difference between patients with normal 
or extended polyQ repeats [53] (Table 1). Furthermore, 
ATXN2 and TDP-43 colocalize in cytoplasmic inclusions 
in FTLD [53], and FUS and ATXN2 have been reported to 
colocalize in ALS [56].
ATXN2 functions in mRNA polyadenylation, stress 
granule formation, polyribosome assembly and miRNA 
synthesis [136, 157, 171] (Fig. 1). The pathological effect 
of extended ATXN2 polyQ repeats is likely due to a gain-
of-function mechanism as ATXN2 knockout mice do not 
show overt neurological deficits [104]. In contrast to SCA2, 
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the polyQ repeats associated with ALS are not pure, i.e., 
containing only CAG codons. Rather, they are composed 
of CAG codons interrupted by CAA codons [216]. As both 
codons encode for the same amino acid, the pathogenic 
effect of ATXN2 polyQ repeat extensions may reside at the 
mRNA level.
Overexpression of ATXN2 with intermediate length 
polyQ repeats does not affect ATXN2 localization [53]. 
However, there is evidence that subcellular distribution of 
overexpressed WT TDP-43 or mutant FUS is altered upon 
overexpression of ATXN2 with intermediate length polyQ 
repeats [53, 56, 152]. Furthermore, ATXN2 with interme-
diate length polyQ repeats enhances stress-induced activa-
tion of caspase-3 as well as cleavage and phosphorylation 
of TDP-43 [77]. So, there is evidence that ATXN2 interme-
diate polyQ repeat modulates ALS pathophysiology via its 
RNA-dependent interaction with FUS and TDP-43, but fur-
ther research is needed to dissect the underlying molecular 
mechanisms.
C9ORF72
An intronic hexanucleotide repeat expansion in C9ORF72 
was recently identified as the most prevalent cause of ALS, 
FTD and ALS-FTD [44, 164]. While in the wild type sit-
uation the gene harbors fewer than 25 repeats, the repeat 
region can be extended to several hundred or thousand 
repeats [15]. Although extended repeat lengths can also be 
detected in control cases, repeat expansions are strongly 
associated with ALS and FTD. Extended repeat lengths 
have also been reported in some cases of Alzheimer’s dis-
ease and Huntington disease-like syndrome [15, 134, 209]. 
C9ORF72 is a protein with unknown function, but shows 
homology to differentially expressed in normal and neo-
plasia (DENN), which is a GDP/GTP exchange factor 
(GEF) that activates Rab GTPases [122, 217] (Fig. 1). The 
expression pattern of C9ORF72 is unaltered in expanded 
repeat carriers, although the specificity of the available 
C9ORF72 antibodies is subject to debate (Table 1). TDP-
43-negative, p62- and UBQLN-positive cytoplasmic and 
nuclear inclusions in the hippocampus, frontotemporal neo-
cortex and cerebellum distinguish expanded repeat from 
non-expanded repeat carriers [2, 27]. Fascinatingly, these 
characteristic inclusions contain poly dipeptide repeat pro-
teins generated by non-ATG-initiated translation from the 
C9ORF72 intronic repeat region [10, 144]. Whether and 
how these dipeptide repeat proteins mediate pathogenic 
effects are unknown and they probably represent one of 
several pathogenic mechanisms in C9ORF72-associated 
ALS. As a second mechanism, C9ORF72 RNA molecules 
containing extended repeats may accumulate and sequester 
RNA binding proteins preventing these proteins from exert-
ing their crucial functions. Similar aggregation of mutant 
RNAs is observed in other repeat expansion disorders. In 
support of this, C9ORF72-containing RNA foci have been 
observed in 25 % of spinal and frontal cortical neurons of 
expanded repeat carriers compared to 1 % in controls [44]. 
This observation has, however, not been confirmed in a sec-
ond, independent study [175]. It has been shown that the 
GGGGCC repeats present in C9ORF72 bind several RNA 
binding proteins and that one of these, hnRNPA3, localizes 
to the p62-positive/TDP-43-negative cytoplasmic inclu-
sions observed in repeat carriers [143]. As a third mecha-
nism, the repeat expansion may result in haploinsufficiency 
due to impaired transcription or splicing. This is supported 
by the finding that C9ORF72 protein levels are reduced in 
patients with increased repeat lengths [44, 68, 144, 193]. 
Finally, in a number of C9ORF72 repeat carriers with 
FTLD, tau pathology has been observed suggesting that the 
C9ORF72 repeat may influence tau protein [20, 106]. Fur-
ther research is needed to address these different mecha-
nisms in relation to ALS disease pathogenesis.
Molecular mechanisms underlying protein aggregation 
in ALS
When studying ALS pathophysiology it is essential, but 
very difficult, to distinguish cause and consequence in the 
cellular cascades driving protein aggregation. The recent 
discovery of new, disease-associated mutations that trigger 
protein aggregation or stability represent unique opportuni-
ties to further dissect the effect and mechanism-of-action 
of protein aggregation in ALS. Several important questions 
need to be addressed including (1) how are proteins seques-
tered into ALS aggregates and (2) how do these aggregates 
affect neuronal function? Several models addressing these 
questions have emerged and will be discussed below.
Low complexity domains in ALS proteins with 
aggregation-prone properties
FUS, TDP-43 and other RNA binding proteins (RBPs) 
contain domains with similarity to yeast prion domains 
(Figs. 1, 2). These domains are enriched for asparagine, 
glutamine, tyrosine and glycine residues and can adopt 
two conformational states: an unfolded and an aggregated 
state. Prion proteins in an aggregated state can sequester 
prion proteins in an unfolded state to adopt the aggre-
gation-prone confirmation and as such aggregation can 
spread. It has been hypothesized that in ALS aggregation 
may propagate from one cell to the other in a comparable 
fashion [107, 162]. Aggregation of FUS and TDP-43 has 
been shown to rely on regions resembling prion domains 
[94, 102, 179] and mutations in TDP-43 associated 
with ALS occur mainly in its prion-like region (Fig. 1). 
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Furthermore, there is direct evidence that ALS proteins 
share features with yeast prion proteins, e.g., that aggre-
gated FUS or TDP-43 can sequester native protein [62, 64, 
102, 215]. Finally, mutations in the prion-like domain of 
the RBP hnRNPA1 segregate with disease in FALS [105]. 
Yeast prions form amyloid deposits characterized by a sec-
ondary beta-sheet structure and stain positive for amyloid 
dyes. Although short synthetic TDP-43 and FUS peptides 
form amyloid-like fibrils in vitro [31, 73, 102] full-length 
TDP-43 does not [95]. Rather, purified full-length FUS 
and TDP-43 form pore-like oligomers and fibrils resem-
bling the ultrastructure of the skein-like inclusions [95, 
179]. However, although initial reports emphasized that 
ALS inclusions lack features of amyloid [148], two recent 
studies found that some TDP-43 positive inclusions stain 
positive for amyloid dyes [21, 166]. Furthermore, to date 
evidence for cell-to-cell spread of ALS aggregated pro-
teins is lacking. Finally, toxicity induced by TDP-43 and 
FUS depends not only on prion-like domains but also on 
RNA binding properties [42, 53, 94, 179, 199]. In all, 
accumulating evidence hints at an important role for prion-
like mechanisms in ALS pathogenesis but further studies 
are needed to uncover their precise mechanism-of-action 
and pathological effects.
Stress granule formation and ALS protein aggregation
Although FUS and TDP-43 have a predominant nuclear 
localization, both proteins rapidly shuttle between the 
nucleus and the cytoplasm and are actively transported into 
axons and colocalize with other RBPs [16, 54, 63, 186, 
202, 224]. RBPs regulate local translation of mRNAs by 
forming granular RNA–protein complexes in which trans-
lation is repressed [5]. Several types of RNA granules can 
be distinguished: stress granules (SG), processing bodies 
(PBs) and so called neuronal or transport granules. These 
granules are highly dynamic structures and interaction and 
exchange of RBPs and transcripts occur between the dif-
ferent types of granules [5]. SGs or PBs are formed fol-
lowing polysome disassembly in response to stress, while 
neuronal granules serve in the transport of mRNA to their 
site of local translation [5]. Interestingly, it has been sug-
gested that the aggregation-prone prion-like domains of 
RBPs assist in the dynamic movement of RBPs in and out 
of RNA granules [102].
ALS-associated mutations in TDP-43, FUS and ATXN2 
are being linked to SGs (Fig. 2). SG formation depends 
on the RRM domains and C-terminal region of TDP-43, 
the same domains required for TDP-43 toxicity [19, 37]. 
Fig. 2  Cellular mechanisms linked to protein aggregation in ALS. 
ALS-associated mutations result in cytoplasmic mislocalization or 
increased aggregation tendency thereby increasing the risk for aber-
rant aggregation. Proteins with domains of low complexity (prion-
like domains) such as FUS, TDP-43 and HNRNPA1 are though to 
be intrinsically aggregation prone. Many of these proteins participate 
in RNA granule formation. ALS-associated mutants alter RNA gran-
ule formation, thereby interfering with the local translation of RNA. 
Moreover, sequestration of ALS-associated proteins and their inter-
actors into cytoplasmic aggregates may result in a loss of function. 
Protein degradation by the UPS and autophagy is essential for the 
clearance of ubiquitinated proteins. Dysfunction of these systems, as 
has been suggested for mutant UBQLN2, OPTN and VCP, can lead to 
proteins deposits
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Although TDP-43 is dispensable for SG formation [19, 37, 
131], depletion of TDP-43 inhibits SG formation [137]. 
WT TDP-43 co-immunoprecipitates and colocalizes with 
stress granule markers, but the effect of mutant TDP-43 is 
less clear [37, 43, 49, 61, 83, 131, 137, 138, 160]. While 
two studies reported an increase in the number of cells 
containing SGs upon TDP-43 mutant overexpression [49, 
131], another study failed to observe such an effect [137]. 
A fourth study did not detect cytoplasmic signals for WT 
or mutant TDP-43 and consequently no colocalization with 
SG markers, although a TDP-43 NLS mutant clearly local-
ized to SGs [19]. Thus, WT TDP-43 likely plays a role in 
SG formation with some evidence for altered SG formation 
associated with mutant TDP-43.
In contrast to TDP-43, mutant but not WT FUS local-
izes to SGs [19, 25, 52, 108, 152, 197]. Whether mutant 
FUS induces SG formation or is recruited to SGs follow-
ing stress is unclear [108, 152, 197]. Similarly, studies 
reporting the effect of FUS mutations or truncations on SG 
recruitment show conflicting results [19, 102, 108]. How-
ever, proteins involved in SG formation have been identi-
fied as modifiers of FUS toxicity in yeast screens [97, 179].
ATXN2 localizes to PBs and SGs following cellular 
stress and its Lsm domain and PAM2 motif are required for 
this localization [152, 157] (Fig. 1). It is unknown whether 
ATXN2 directly regulates RNA granule formation or func-
tion. However, overexpression of ATXN2 31Q increases the 
cytoplasmic localization of TDP-43 following heat shock 
[53] and increases the cytoplasmic localization of mutant 
FUS, but without affecting SG formation [56].
In conclusion, FUS, TDP-43 and ATXN2 have all been 
implicated in SG formation and there is evidence that alter-
ations in SG formation are associated with ALS-associated 
mutant proteins. Interestingly, HNRNPA1 localizes to SGs 
as well and ALS-associated mutations in HNRNPA1 aug-
ment its incorporation into SGs [105]. However, while the 
formation of RNA granules is normally a reversible pro-
cess, in ALS disrupted RNA granule formation is hypothe-
sized to result in insoluble aggregates. The most convincing 
evidence for this comes from pathological examination of 
ALS spinal cords. Although one study did not detect colo-
calization of TDP-43 positive inclusions with SG markers 
in SALS motor neurons [37], three other studies, using 
more sensitive methods, convincingly did [19, 131, 200]. 
Furthermore, the SG markers PABP-1 and eIF4G colocalize 
with FUS aggregates in spinal cord of FUS mutation carri-
ers [52]. Whether these aggregates have primarily formed 
as SGs or reflect a more general sequestration of interact-
ing proteins in FUS and TDP-43 aggregates (see below), 
remains to be shown. Furthermore, how reversible SGs 
develop into insoluble aggregates is unknown. Increased 
cytoplasmic localization of FUS and TDP-43, increased 
aggregation tendency of mutant RBPs and phosphorylation 
of RBPs have been suggested to regulate their localiza-
tion to SGs [102, 108, 138] and may be altered in ALS. An 
altered RNA binding preference of mutant RBPs could also 
underlie altered RNA granule formation [84]. How RNA 
granule formation and disassembly are dysregulated in 
ALS and which transcripts are affected by these processes 
will undoubtedly be a focus of further investigations.
Protein sequestering
Cytoplasmic aggregation of ALS proteins at ectopic sites 
in the cell may prevent these proteins from executing their 
normal function (Fig. 2). If this mechanism would be 
solely responsible for ALS pathogenesis, gene knockdown 
or knockout is expected to result in strong motor neuron 
phenotypes. Unfortunately, FUS and TDP-43 are essential 
for normal development and knockout of FUS or TDP-
43 results in premature death in mice [81, 112, 115, 172]. 
There is some evidence that knockdown of FUS or TDP-
43 results in motor dysfunction in Drosophila and zebrafish 
models [58, 98, 99, 128, 170, 203] (Supplementary Table). 
However, the relevance of these findings in the context ALS 
is unclear as knockdown often triggers abnormalities out-
side the nervous system as well and motor neuron degen-
eration is not consistently observed. Additional models are 
needed to study the effect of reduced levels of proteins like 
FUS and TDP-43 but it seems unlikely that reduced levels 
of these proteins alone cause ALS.
On the other hand, FUS and TDP-43 aggregation could 
exert a toxic effect via sequestration of multiple binding 
partners or even interactomes essential for neuronal func-
tion. FUS and TDP-43 interact and colocalize with many 
different proteins including SMN, gemin proteins and 
small nuclear ribonucleoprotein particles (snRNPs) [188, 
214] (Fig. 1). The SMN complex can be detected in the 
cytoplasm, but also in nuclear foci called GEMs. Knock-
down of FUS or TDP-43 results in the loss of GEMs [173, 
188]. Furthermore, a reduced number of GEMs is observed 
in ALS spinal cord motor neurons [188], fibroblasts derived 
from FUS or TDP-43 mutation carriers [214] and ALS 
mouse models [65, 101, 173]. Therefore, sequestration 
of SMN in FUS or TDP-43 cytoplasmic aggregates could 
affect SMN levels and function.
The idea that aggregation of proteins, such as TDP-43, 
leads to the sequestering of other essential proteins is sup-
ported by a recent study identifying the lariat debranch-
ing enzyme Dbr1 as a modifier of TDP-43 toxicity [8]. 
Dbr1 normally mediates the degradation of intronic lari-
ats. Knockdown of Dbr1 triggers the transport of exces-
sive lariat RNAs into the cytoplasm where they bind 
TDP-43. Since this leads to a reduction in cellular toxic-
ity it was proposed that knockdown of Dbr1 reduces TDP-
43 toxicity by capturing TDP-43 and thereby diminishing 
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sequestration of RNAs and RBPs in TDP-43 aggregates. 
Although currently functional evidence for RNA and pro-
tein sequestering by ALS-associated protein aggregates 
is scarce, these recent findings warrant a more extensive 
study of the ability of ALS-associated protein aggregates 
to sequester RNAs and RBPs and of the effect this has on 
motor neuron homeostasis.
Dysfunction of protein degradation pathways
Molecular chaperones, the UPS, and the autophagy-lyso-
some system function to monitor protein quality and protect 
cells from dysfunctional, malfolded or denatured proteins. 
The presence of ubiquitin, p62 and molecular chaperones 
in ALS aggregates implicates a role for all these three sys-
tems in ALS pathophysiology (Fig. 2).
Chaperone molecules assist in protein folding under 
physiological circumstances and prevent protein aggrega-
tion in response to stress. They also assist in protein degra-
dation by the proteasome or autophagy. Chaperones, such 
as heat shock proteins, are upregulated in ALS spinal cord 
[4] and present in motor neuron aggregates [14, 204]. Inter-
estingly, upregulation of molecular chaperones increases 
solubility and reduces toxicity of FUS [139] and TDP-43, 
especially of TDP-43 C-terminal fragments [40, 71]. In line 
with this, knockdown of molecular chaperones increases 
accumulation of pTDP-43 C-terminal fragments [220] and 
enhances toxicity of TDP-43 overexpression [219]. Thus, 
chaperone molecules are likely to play a significant role in 
aggregation of ALS proteins and in their toxic effects.
Ubiquitination not only marks proteins for degradation 
but also mediates intracellular signaling, e.g., NFκB acti-
vation [114]. As proteins present in ALS aggregates are 
ubiquitinated it has been postulated that they are marked 
for degradation by the UPS, but eventually deposit when 
dysfunctional protein levels exceed UPS capacity. In line 
with this, examination of ALS spinal cord tissue shows 
that ubiquitination occurs before accumulation starts and 
that inclusion formation inversely correlates to the num-
ber of motor neurons, indicating that deposition of ubiq-
uitinated proteins relates to toxicity [69]. Consistently, 
proteasome inhibition has been found to increase endog-
enous TDP-43 levels, blocks degradation of overexpressed 
TDP-43 C-terminal fragments and enhances toxicity [88, 
155, 194, 220]. Recently, motor neuron-specific knockout 
of the proteasome subunit Rpt3 was reported to result in 
the loss of spinal motor neurons and locomotor dysfunc-
tion in mice [183]. Interestingly, these mice contained 
basophilic, hyaline and skein-like inclusions positive for 
TDP-43, FUS, UBQLN2 and OPTN, indicating that dys-
function of the proteasome itself is sufficient to induce 
aggregation of ALS-associated proteins and motor neuron 
degeneration. The fact that mutations in UBQLN2 cause 
ALS and are associated with impaired UPS function fur-
ther underlines the notion that proteasomal degradation 
does not only modulate but also may play a causative role 
in ALS pathogenesis.
p62 serves as an adaptor of autophagic degradation 
by binding both polyubiquitinated proteins and LC3, an 
important autophagosomal marker. Autophagy mediates 
the degradation of TDP-43 C-terminal fragments, but 
not full-length protein [30, 93, 182]. Interestingly, treat-
ment of transgenic TDP-43 mice with autophagic activa-
tors reduces locomotor dysfunction, learning and memory 
deficits, and neuron loss [201]. This is accompanied by 
a decrease in cytosolic TDP-43 inclusions and in insolu-
ble full-length and truncated TDP-43. This indicates that 
autophagic clearance of TDP-43 reduces neurotoxic-
ity. Knockout mice lacking Atg7 or Atg5 in the central 
nervous system, genes essential for autophagy, display 
movement disorders, widespread neurodegeneration and 
ubiquitin-positive inclusions in a variety of brain regions 
[75, 109]. Motor neuron-specific knockout of these genes 
results in ubiquitinated and p62-positive inclusions, but 
do not stain for TDP-43, FUS, OPTN or UBQLN2 and 
do not result in motor neuron death [183]. This would 
suggest that autophagic disruption does not primarily 
underlie ALS pathogenesis. However, mutations in genes 
encoding autophagy regulators have been associated with 
ALS, i.e., VCP, p62, CHMP2B and UBQLN2 [47, 57, 
96, 161]. Patients with mutations in SQSTM1, the gene 
encoding p62, show large round p62-positive inclusions 
in motor neurons with additional TDP-43 deposits which 
are p62-negative [184]. Furthermore, TDP-43 has been 
identified as a modifier of mutant VCP toxicity [165] and 
ubiquilins have been reported to modulate TDP-43 toxic-
ity in Drosophila [74]. In conclusion, components of the 
protein degradation pathways have emerged as important 
modulators of protein aggregation and toxicity in ALS. 
Furthermore, mutations in genes encoding these compo-
nents have been associated with ALS indicating a causal 
role in the disease. Future studies are needed to investigate 
how these processes are affected in ALS, as they may rep-
resent potential therapeutic targets.
Conclusions
Protein aggregation in affected motor neurons is a central 
hallmark of ALS, and recent genetic, cellular and histo-
logical studies have enlarged our understanding of the 
molecular composition of these aggregates. This has led 
to the identification of new ALS causing genes, has linked 
the composition of aggregates to specific genetic defects, 
and has provided starting points for further investigation 
of underlying molecular pathways. Unique pathological 
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features have now been identified that distinguish FUS, 
SOD1 and C9ORF72 mutation carriers from other ALS 
cases. It is likely that with future discoveries further clas-
sification will be possible. TDP-43, FUS, p62, OPTN and 
UBQLN2 show a widespread distribution in ALS-linked 
aggregates. This could reflect a general role in pathogen-
esis or, on the contrary, question their specific relevance 
to disease. However, the fact that mutations in the genes 
encoding these proteins segregate with disease in FALS 
supports the idea that their dysfunction is linked to motor 
neuron degeneration and disease pathogenesis. The pro-
teins identified to be present in ALS aggregates play a role 
in a wide range of cellular processes with a marked over-
lapping role for TDP-43, FUS and ATXN2 in RNA metab-
olism and for OPTN, UBQLN2 and VCP in protein qual-
ity control and degradation (Fig. 2). How a disturbance of 
these ubiquitously expressed proteins can result in motor-
neuron-specific degeneration remains an unresolved issue 
in the field of ALS research. Although cellular and animal 
models confirm a role for aggregation in ALS, results are 
often contradictory and models fully recapitulating ALS 
pathogenesis are mostly lacking. This may in part be 
explained by the fact that many of these models rely on 
overexpression of the protein. New model systems, such as 
iPSC-generated patient-derived cell lines or inducible ani-
mal models, may help to overcome these problems. So far, 
TDP-43 and FUS have been investigated most extensively; 
future studies on the role of OPTN, UBQLN2, ATXN2 and 
C9ORF72 will further enlarge our understanding of the 
cellular processes underlying ALS. Processes underlying 
aggregation in ALS include enhanced intrinsic aggregation 
propensity of ALS proteins, RNA granule dysregulation 
and dysfunction of protein degradation pathways. A fur-
ther understanding of these processes will not only deepen 
our understanding of ALS pathogenesis, but also may aid 
the development of novel therapeutic strategies for this 
disease.
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